To investigate whether mitochondrial biogenesis affects SIRT6's resistance to cholestatic liver disease, we administered AICAR to liver-specific Sirt6 knockout mice to activate the AMPK/PGC-1α pathway, or used KNI-1 to activate NRF2. Here, NFE2L2 is linked to Cholestatic liver disease.